RenovoRx, Inc. Form 8-K Summary
Business Context and Reporting Period
RenovoRx, Inc. (RNXT), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on March 30, 2023. The filing details a material definitive agreement entered into on the same date regarding a capital raise. The transaction closed on April 3, 2023.
Key Financial Metrics and Transaction Details
The Company executed a Registered Direct Offering and a concurrent private placement. Key financial terms include:
- Gross Proceeds: Approximately $5.00 million (before deducting placement agent fees).
- Offering Price: $3.21 per share for Common Stock and $3.2099 per Pre-Funded Warrant.
- Securities Issued:
- 1,000,000 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 557,632 shares (exercise price $0.0001).
- Common Warrants to purchase up to 1,947,040 shares (exercise price $3.21, expiring 5.5 years from issuance).
- Placement Agent Fees: 7.0% of aggregate gross proceeds plus reimbursement of out-of-pocket expenses up to $50,000.
- Use of Proceeds: General corporate purposes, including working capital.
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels as this is a transactional report rather than a periodic financial statement.
Material Changes and Agreements
The primary material change is the increase in share count and the issuance of warrants. The Company entered into a Securities Purchase Agreement with an institutional investor and a Placement Agency Agreement with Roth Capital Partners, LLC. The agreement includes a 60-day lock-up period for the Company and its executive officers/directors regarding the sale of Common Stock or equivalents. Additionally, the Company agreed not to issue new Common Stock or equivalents for 60 days post-closing and is restricted from Variable Rate Transactions for one year (with an exception for at-the-market offerings after six months).
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds to support working capital and general corporate needs. The filing notes standard risks associated with the issuance of unregistered securities (Common Warrants) and the dilution of existing shareholders. The Company has agreed to indemnify the Placement Agent against certain liabilities. No specific forward-looking guidance regarding future revenue or earnings was provided in this document.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% placement fee and the $50,000 expense cap.
- Confirm the exact number of Pre-Funded Warrants exercised, as this was subject to the Purchaser's discretion regarding beneficial ownership limits (4.99% or 9.99%).
- Review the impact of the 1,947,040 Common Warrants on future dilution if exercised at the $3.21 strike price.
- Check subsequent filings for the 60-day lock-up expiration and any new capital raises.